The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MNOV | -29.48% | -77.57% | -25.83% | -89% |
| S&P | +16.23% | +94.45% | +14.22% | +379% |
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors.
The biotech announced a major new development partnership.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.13M | 0.0% |
| Gross Profit | $0.01M | 345.5% |
| Gross Margin | 9.80% | 0.0% |
| Market Cap | $64.25M | -9.0% |
| Market Cap / Employee | $4.94M | 0.0% |
| Employees | 13 | 0.0% |
| Net Income | -$3.28M | -24.8% |
| EBITDA | -$3.60M | -18.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $34.26M | -22.7% |
| Accounts Receivable | $0.13M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.12M | -61.3% |
| Short Term Debt | $0.18M | -2.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -21.43% | -8.8% |
| Return On Invested Capital | -17.19% | -0.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.31M | 18.0% |
| Operating Free Cash Flow | -$2.31M | 17.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.79 | 1.87 | 1.36 | 1.29 | 9.01% |
| Price to Sales | 73.57 | 71.12 | 70.63 | 477.35 | - |
| Price to Tangible Book Value | 2.40 | 2.53 | 1.88 | 1.81 | 16.32% |
| Enterprise Value to EBITDA | -18.52 | -19.83 | -11.07 | -8.41 | -4.50% |
| Return on Equity | -17.2% | -19.2% | -20.3% | -22.7% | 70.09% |
| Total Debt | $0.46M | $0.41M | $0.36M | $0.30M | -38.71% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
